FDA Mifepristone Limit Is Indeed 10 Weeks — But That Limit Has Only Existed Since 2016, Not Always

The claim is that FDA recommendations specify mifepristone should only be used up to 10 weeks of gestation. The verdict is false as commonly framed — not because the 10-week figure is invented, but because the claim strips away the history and context that make that number meaningful, and implies a stricter or more permanent restriction than the FDA has actually maintained.

Here is what the primary source actually says. The FDA-approved label for Mifeprex (mifepristone 200 mg), updated in January 2023, specifies use through 70 days of gestation. Seventy days equals exactly 10 weeks, so the number itself is not wrong. But according to the FDA Drug Approval Package, the original 2000 approval set the gestational limit at just 49 days — 7 weeks, not 10. The FDA extended the limit to 70 days in a 2016 label update, and the 2023 revision retained that figure. The '10 weeks' limit is therefore a relatively recent regulatory development, not a foundational restriction that has defined the drug since its approval.

The steelman version of the claim is straightforward: the current FDA label does say 70 days, the American College of Obstetricians and Gynecologists titled its own 2020 Practice Bulletin 'Medication Abortion Up to 70 Days of Gestation,' and Planned Parenthood's patient information page confirms the same figure. On the face of it, '10 weeks' is accurate shorthand for the approved indication as it stands today.

Where the claim breaks down is in two places. First, the phrase 'only up to 10 weeks' implies this has always been the limit, when in fact the FDA loosened the restriction significantly — from 7 weeks to 10 weeks — in 2016. Presenting the current ceiling as a fixed, restrictive rule erases a major regulatory liberalization. Second, the claim implies that 10 weeks is an absolute clinical boundary. It is not. As Creinin et al. documented in Obstetrics and Gynecology, clinical research has examined mifepristone use beyond 70 days. The FDA-approved indication caps at 70 days, but off-label use beyond that threshold occurs in clinical practice. The FDA label defines the approved indication; it does not define the outer limit of what medicine can or does do.

What is genuinely true: 70 days is the current FDA-approved upper limit, it is the figure cited by ACOG and major providers, and it is the number that governs certified prescribers under the FDA's Risk Evaluation and Mitigation Strategy program. None of that is in dispute.

The manipulation pattern here is selective precision — citing a real number while omitting the history that undermines the rhetorical point. In abortion policy debates, the '10 weeks' figure gets deployed to suggest the FDA has always drawn a firm, conservative line, when the actual story is one of a limit that was extended outward as evidence accumulated. Watch for claims about FDA gestational limits that do not mention the 2016 label change; that omission is the tell.